EAST NORRITON, Pa., Oct. 27 /PRNewswire/ — Tengion, Inc.
(Nasdaq:
TNGN), a leader in regenerative medicine, reviewed pipeline
progress at its first Analyst and Investor Meeting which was held
today in New York City.  The event featured updates and
discussions of milestones and key data for the Company’s
Neo-Urinary Conduit™ and Neo-Kidney Augment™ programs.
 An audio archive of the event and presentation materials will
be available at the Investors section of the Tengion website at www.tengion.com.  

Neo-Urinary Conduit Bladder Cancer Trial – Clinical
Update

The Company’s Neo-Urinary Conduit was recently implanted in the
first patient as part of the ongoing initial clinical trial
evaluating the Company’s lead product candidate in bladder cancer
patients requiring a urinary diversion following bladder removal.
The patient is being treated at the University of Chicago Medical
Center by the principal investigator at the site for this study,
Gary D. Steinberg, M.D., Professor of Surgery and Director,
Urologic Oncology.  The trial is also being conducted at The
Johns Hopkins Hospital in Baltimore, Maryland.

“We are very pleased that investigators have identified,
enrolled, biopsied, and implanted the first patient with our
regenerative Neo-Urinary Conduit,” stated Sunita Sheth, M.D., vice
president and chief medical officer.  “With the first implant
completed and two sites actively screening patients, we and our
investigators are optimistic that the pace of enrollment will
accelerate.”

Neo-Kidney Augment Program Update

The Neo-Kidney Augment is the Company’s lead preclinical program
and is intended to prevent or delay the need for dialysis or kidney
transplant by increasing functional renal mass in patients with
advanced chronic renal disease, a significant

‘/>”/>

SOURCE